It's possible, but we don't have any data on that. We have data on the decrease in the risk of developing a severe form COVID‑19 or dying, but the consequences for less severe cases in the acute phase have yet to be determined. Consideration should also be given to the prophylactic effect this could have after exposure to COVID‑19. It is a very interesting hypothesis that should be studied.
Another question is whether PAXLOVID could treat long COVID‑19. That's another issue that certainly needs more study. For the moment, what we are seeing are anecdotal situations that seem to indicate, in some cases, that there might be an improvement in the symptoms, but we don't know how long that improvement will last.